ABSTRACT
We report here on HIV-1 immunization results in rabbits and macaques co-immunized with clade C gp160 DNA and gp140 trimeric envelope vaccines, a strategy similar to a recent clinical trial that showed improved speed and magnitude of humoral responses. Clade C envelopes were isolated from CAP257, an individual who developed a unique temporal pattern of neutralization breadth development, comprising three separate "Waves" targeting distinct Env epitopes and different HIV clades. We used phylogeny and neutralization criteria to down-select envelope vaccine candidates, and confirmed antigenicity of our antigens by interaction with well-characterized broadly neutralizing monoclonal antibodies. Using these envelopes, we performed rabbit studies that screened for immunogenicity of CAP257 Envs from timepoints preceding peak neutralization breadth in each Wave. Selected CAP257 envelopes from Waves 1 and 2, during the first 2 years of infection that were highly immunogenic in rabbits were then tested in macaques. We found that in rabbits and macaques, co-immunization of DNA, and protein envelope-based vaccines induced maximum binding and neutralizing antibody titers with three immunizations. No further benefit was obtained with additional immunizations. The vaccine strategies recapitulated the Wave-specific epitope targeting observed in the CAP257 participant, and elicited Tier 1A, 1B, and Tier 2 heterologous neutralization. CAP257 envelope immunogens also induced the development of ADCC and TFH responses in macaques, and these responses positively correlated with heterologous neutralization. Together, the results from two animal models in this study have implications for identifying effective vaccine immunogens. We used a multi-step strategy to (1) select an Env donor with well-characterized neutralization breadth development; (2) study Env phylogeny for potential immunogens circulating near peak breadth timepoints during the first 2 years of infection; (3) test down-selected Envs for antigenicity; (4) screen down-selected Envs in an effective vaccine regimen in rabbits; and (5) advance the most immunogenic Envs to NHP studies. The results were an induction of high titers of HIV-1 envelope-specific antibodies with increasing avidity and cross-clade neutralizing antibodies with effector functions that together may improve the potential for protection in a pre-clinical SHIV model.
Subject(s)
AIDS Vaccines/administration & dosage , Broadly Neutralizing Antibodies/blood , HIV Antibodies/blood , HIV Envelope Protein gp160/administration & dosage , HIV Infections/prevention & control , HIV-1/immunology , Immunization , Immunogenicity, Vaccine , env Gene Products, Human Immunodeficiency Virus/administration & dosage , AIDS Vaccines/immunology , Animals , Broadly Neutralizing Antibodies/immunology , Epitopes , Female , HIV Antibodies/immunology , HIV Envelope Protein gp160/genetics , HIV Envelope Protein gp160/immunology , HIV Infections/immunology , HIV Infections/virology , HIV-1/genetics , Immunity, Humoral , Macaca mulatta , Male , Rabbits , Time Factors , Vaccines, DNA/administration & dosage , Vaccines, DNA/immunology , env Gene Products, Human Immunodeficiency Virus/genetics , env Gene Products, Human Immunodeficiency Virus/immunologyABSTRACT
BACKGROUND: Prime-boost regimens comprising ALVAC-HIV (prime) and human immunodeficiency virus type 1 (HIV) Env (boost) induce HIV-specific neutralizing antibody and cell-mediated immune responses, but the impact of boost schedule and adjuvant requires further definition. METHODS: A phase 1 trial was conducted. In part A (open label), 19 volunteers received oligomeric glycoprotein 160 from HIV strains MN and LAI-2 (ogp160 MN/LAI-2) with dose escalation (25, 50, 100 µg) and either polyphosphazene (pP) or alum adjuvant. In part B, 72 volunteers received either placebo (n=12) or recombinant canarypox virus expressing HIV antigens (ALVAC-HIV [vCP205]) with different doses and schedules of ogp160 MN/LAI-2 in pP or alum (n = 60). RESULTS: The vaccines were safe and well tolerated, with no vaccine-related serious adverse events. Anti-gp70 V1V2 antibody responses were detected in 17 of 19 part A volunteers (89%) and 10%-100% of part B volunteers. Use of a peripheral blood mononuclear cell-based assay revealed that US-1 primary isolate neutralization was induced in 2 of 19 recipients of ogp160 protein alone (10.5%) and 5 of 49 prime-boost volunteers (10.2%). Among ogp160 recipients, those who received pP were more likely than those who received alum to have serum that neutralized tier 2 viruses (12% vs 0%; P = .015). CONCLUSIONS: Administration of ogp160 with pP induces primary isolate tier 2 neutralizing antibody responses in a small percentage of volunteers, demonstrating proof of concept and underscoring the importance of further optimization of prime-boost strategies for HIV infection prevention. CLINICAL TRIALS REGISTRATION: NCT00004579.
Subject(s)
AIDS Vaccines/immunology , Adjuvants, Immunologic/administration & dosage , HIV Antibodies/blood , HIV Envelope Protein gp160/immunology , HIV Infections/prevention & control , HIV-1/immunology , AIDS Vaccines/administration & dosage , Adolescent , Adult , Alum Compounds/administration & dosage , Antibodies, Neutralizing , Female , HIV Antibodies/immunology , HIV Antigens/administration & dosage , HIV Antigens/immunology , HIV Envelope Protein gp160/administration & dosage , HIV Infections/immunology , HIV Infections/virology , Humans , Immunization , Leukocytes, Mononuclear/immunology , Male , Middle Aged , Organophosphorus Compounds/administration & dosage , Polymers/administration & dosage , Young AdultABSTRACT
We have previously reported that the cytotoxic activity of murine CD8(+) CTLs specific for HIV-1 gp160 envelope protein was markedly inhibited in vitro by brief exposure to a free epitope peptide P18-I10 (aa: RGPGRAFVTI) using the epitope-specific CTL line (LINE-IIIB) or a clone (RT-1). We have also shown that recently stimulated P18-I10-specific murine CTLs rapidly fell into apoptosis in vitro after brief exposure to the free epitope peptide. In the present study, we examined whether similar inactivation or apoptosis of recently stimulated CTLs occurred in vivo by exposure to the free epitope peptide using TCR transgenic (Tg-RT-1) mice expressing TCRαß genes of CTL clone RT-1. When the Tg mice were inoculated with recombinant vaccinia virus expressing HIV-1-IIIB gp160 genes followed by injection of P18-I10 epitope peptide, apparent reduction in the number of CTLs determined by flow cytometry using H-2D(d)/P18-I10 pentamer was observed within a few hours after the injection. Most of the H-2D(d)/P18-I10 pentamer-stained cells were positive for Annexin V and apoptosis was confirmed by microscopic analyses. Moreover, when mice were pretreated with immunosuppressive agents, such as cyclosporin A and tacrolimus (FK506), induction of apoptosis by P18-I10 was significantly inhibited and CTL cytotoxicity was maintained. These results suggest that the rapid loss of virus-specific CD8(+) CTLs might occur in vivo through apoptosis in the early stages of viral infection when activated CTLs may encounter viral epitope(s) released from virus-infected cells attacked by CTLs and we can prevent the loss by pretreatment with immunosuppressive agents.
Subject(s)
Apoptosis/drug effects , HIV Envelope Protein gp120/immunology , HIV Envelope Protein gp160/immunology , HIV-1/immunology , Histocompatibility Antigens Class I/immunology , Peptide Fragments/immunology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Animals , Apoptosis/immunology , CD8 Antigens/genetics , CD8 Antigens/immunology , Cyclosporine/administration & dosage , Epitopes/genetics , Epitopes/immunology , Genetic Vectors , HIV Antigens/administration & dosage , HIV Antigens/immunology , HIV Envelope Protein gp120/administration & dosage , HIV Envelope Protein gp160/administration & dosage , Immunosuppressive Agents/administration & dosage , Mice , Mice, Transgenic , Molecular Sequence Data , Peptide Fragments/administration & dosage , Receptors, Antigen, T-Cell, alpha-beta/genetics , Receptors, Antigen, T-Cell, alpha-beta/immunology , T-Lymphocytes, Cytotoxic/virology , Tacrolimus/administration & dosage , Vaccinia virus/genetics , Vaccinia virus/immunologyABSTRACT
To obtain proof of concept for HIV vaccines, we generated recombinant multimeric particles displaying the HIV-1 Envelope (Env) third hypervariable region (V3) as an N-terminal fusion protein on the E2 subunit of the pyruvate dehydrogenase complex of Geobacillus stearothermophilus. The E2 scaffold self-assembles into a 60-mer core that is 24 nm in diameter, with a molecular weight of 1.5 MDa, similar to a virus like particle with up to 60 copies of a heterologous protein accessible on the surface. Env(V3)-E2 multimers were tested alone and in combination with Env(gp160) DNA in mice and rabbits. Following two or more co-immunizations with Env(V3)-E2 and Env gp160 DNA, all 18 rabbits developed potent autologous neutralizing antibodies specific for V3 in six weeks. These neutralizing antibodies were sustained for 16 weeks without boosting, and comparable responses were obtained when lipopolysaccharide, a contaminant from expression in E. coli, was removed. Co-immunizations of Env(V3)-E2 and DNA expressing gp160 elicited moderate CD8-specific responses and Env-specific antibodies in mice. Co-immunization with DNA and E2 was superior to individual or sequential vaccination with these components in eliciting both neutralizing antibodies in rabbits and CD8(+) T cell responses in mice. Co-immunization with DNA and multimeric E2 scaffolds appears to offer a highly effective means of eliciting rapid, specific, and sustained immune responses that may be a useful approach for other vaccine targets.
Subject(s)
AIDS Vaccines/immunology , CD8-Positive T-Lymphocytes/immunology , HIV Antibodies/biosynthesis , HIV-1 , Immunization/methods , Animals , Antibodies, Neutralizing/biosynthesis , DNA/administration & dosage , Gene Products, env , HIV Envelope Protein gp160/administration & dosage , HIV Envelope Protein gp160/genetics , Humans , Mice , Particle Size , RabbitsABSTRACT
We sought to induce primate immunodeficiency virus-specific cellular and neutralizing antibody (nAb) responses in rhesus macaques (RM) through a bimodal vaccine approach. RM were immunized intragastrically (i.g.) with the live-attenuated Listeria monocytogenes (Lm) vector Lmdd-BdopSIVgag encoding SIVmac239 gag. SIV Gag-specific cellular responses were boosted by intranasal and intratracheal administration of replication-competent adenovirus (Ad5hr-SIVgag) encoding the same gag. To broaden antiviral immunity, the RM were immunized with multimeric HIV clade C (HIV-C) gp160 and HIV Tat. SIV Gag-specific cellular immune responses and HIV-1 nAb developed in some RM. The animals were challenged intrarectally with five low doses of R5 SHIV-1157ipEL-p, encoding a heterologous HIV-C Env (22.1% divergent to the Env immunogen). All five controls became viremic. One out of ten vaccinees was completely protected and another had low peak viremia. Sera from the completely and partially protected RM neutralized the challenge virus > 90%; these RM also had strong SIV Gag-specific proliferation of CD8⺠T cells. Peak and area under the curve of plasma viremia (during acute phase) among vaccinees was lower than for controls, but did not attain significance. The completely protected RM showed persistently low numbers of the α4ß7-expressing CD4⺠T cells; the latter have been implicated as preferential virus targets in vivo. Thus, vaccine-induced immune responses and relatively lower numbers of potential target cells were associated with protection.
Subject(s)
Adenoviridae/immunology , Gene Products, gag/immunology , HIV Envelope Protein gp160/immunology , Listeria monocytogenes/immunology , tat Gene Products, Human Immunodeficiency Virus/immunology , Adenoviridae/genetics , Animals , Antibodies, Neutralizing/blood , Antigens, Viral/genetics , Antigens, Viral/immunology , CD4-Positive T-Lymphocytes , CD8-Positive T-Lymphocytes , Enzyme-Linked Immunospot Assay , Gene Products, gag/administration & dosage , HIV Envelope Protein gp160/administration & dosage , HIV Infections/prevention & control , HIV-1/immunology , Immunity, Mucosal , Immunization, Secondary , Interferon-gamma/analysis , Listeria monocytogenes/genetics , Macaca mulatta/immunology , Macaca mulatta/virology , Simian Immunodeficiency Virus/immunology , Vaccination , Viral Load , Viremia/immunology , tat Gene Products, Human Immunodeficiency Virus/administration & dosageABSTRACT
This study was designed to determine the impact of maternal HIV-1 specific immunity on HIV-DNA immunization of 2-week-old pups during the breast-feeding period. Adult female mice received intranasal or intradermal HIV-DNA (gp160Env, p37Gag, Nef, Tat and Rev) prime and recombinant protein boost immunizations, which induced mucosal and systemic HIV-1 specific B and T cell responses. Intranasal administration of the immunogens induced higher serum IgG titers to HIV antigens than intradermal immunization. Furthermore, high HIV-1 specific fecal IgA titers were obtained in mice immunized by intranasal administration. The capacity to respond to the same immunogens (one single prime with DNA and one boost with recombinant protein) was then compared in pups born to mothers with HIV-1-specific immune responses and pups born to non-vaccinated mothers. Immune responses to the largest number of antigens were detected in pups born to mothers with the highest HIV-1-specific immune responses. These data show that HIV-1 DNA-plasmid immunization during breast-feeding and recombinant protein boosting shortly thereafter enhance the breadth of humoral HIV-1-specific immune responses.
Subject(s)
AIDS Vaccines , Adjuvants, Immunologic , HIV Antibodies/blood , HIV Infections/immunology , HIV-1/immunology , Human Immunodeficiency Virus Proteins/immunology , Vaccines, DNA , AIDS Vaccines/administration & dosage , AIDS Vaccines/genetics , AIDS Vaccines/immunology , Animals , Animals, Newborn , B-Lymphocytes/immunology , Breast Feeding , Female , HIV Antibodies/immunology , HIV Envelope Protein gp160/administration & dosage , HIV Envelope Protein gp160/genetics , HIV Envelope Protein gp160/immunology , HIV Infections/prevention & control , HIV Infections/virology , Human Immunodeficiency Virus Proteins/administration & dosage , Human Immunodeficiency Virus Proteins/genetics , Immunity, Maternally-Acquired , Immunization, Secondary , Mice , Mice, Inbred C57BL , Mucous Membrane/immunology , Recombinant Proteins/administration & dosage , Recombinant Proteins/genetics , Recombinant Proteins/immunology , T-Lymphocytes/immunology , Vaccines, DNA/administration & dosage , Vaccines, DNA/genetics , Vaccines, DNA/immunologyABSTRACT
OBJECTIVE: To evaluate functional potential and phenotypic markers in HIV-1-infected patients immunized with HIV-1 rgp160. METHODS: We assessed changes in T-cell phenotype and immune function in 12 HIV-1-infected individuals that were part of a therapeutic vaccine study from 1992 to 1995 [Sandstrom E, Wahren B. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet 1999;353(9166):1735-42]. The patients received 160 microg HIV-1 rgp160 or placebo i.m. at baseline (day 0), and months 1, 2, 3, 4, 6, and thereafter every 3 months. Frozen peripheral blood mononuclear cells (PBMC) were retrieved from time points 0, 9, 12 and 24 months for phenotypic analysis utilizing flow cytometry. RESULTS: Up-regulation of immune activation markers HLA-DR and CD38 was observed at baseline and throughout the monitoring period on both CD4+ and CD8+ T cells in all patients, reflecting immune activation due to persistent high viral load. Further enhanced expression of activation markers was observed over time in the vaccine group, but not the placebo group. We also observed a consistent long-term increase of the CD4+ central memory population (CD3+CD4+CD45RA-CCR7+) in the vaccinated group. CONCLUSIONS: Administration of eight doses of rgp160 in a year appeared to partially reverse some of the defects exerted by HIV-1 on the immune system. A combination of vaccination with effective antiretroviral therapy (ART) may thus represent an immunotherapeutic intervention for treatment of chronic HIV-1 infection. The improvement of a HIV-1-specific central memory population and HIV-1 antigen-specific CD4+ lymphoproliferative responses may have contributed to the short-term improved survival reported in the vaccinated group.
Subject(s)
AIDS Vaccines , CD4-Positive T-Lymphocytes/immunology , HIV Envelope Protein gp160/immunology , HIV Infections/prevention & control , Immunologic Memory , AIDS Vaccines/administration & dosage , AIDS Vaccines/genetics , AIDS Vaccines/immunology , CD4 Lymphocyte Count , HIV Envelope Protein gp160/administration & dosage , HIV Envelope Protein gp160/genetics , HIV Envelope Protein gp160/therapeutic use , HIV Infections/immunology , HIV Infections/virology , HIV-1/immunology , Humans , Immunization , Recombinant Proteins/administration & dosage , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Recombinant Proteins/therapeutic use , Time FactorsABSTRACT
In this study, immunizations at 2 weeks vs. 6 weeks intervals, with an HIV-1 envelope protein in adjuvants, through intra-nasal (IN), intra-muscular (IM), IN followed by IM (IN/IM) and IM/IN, were compared for induction of mucosal and systemic immune responses. IN/IM immunizations at 2, but not at 6, week intervals induced the highest mucosal and systemic immune responses compared to other immunization routes. Following a resting memory phase, IN boosting of IN/IM-immunized mice, compared to IM-boosting of IM-immunized mice, induced increased IgA responses. Thus, depending on the immunization intervals, IN/IM may be more effective than IM immunizations for short- and long-term immunity.
Subject(s)
AIDS Vaccines/administration & dosage , AIDS Vaccines/immunology , HIV Envelope Protein gp160/administration & dosage , HIV Envelope Protein gp160/immunology , Immunity, Mucosal , Immunologic Memory , AIDS Vaccines/genetics , Administration, Intranasal , Animals , Cytokines/biosynthesis , Female , HIV Antibodies/analysis , HIV Envelope Protein gp160/genetics , Immunization, Secondary , Immunoglobulin A/blood , Immunoglobulin G/blood , Injections, Intramuscular , Mice , Mice, Inbred BALB C , T-Lymphocytes/immunology , Time FactorsABSTRACT
BACKGROUND: The development of an effective HIV-1 vaccine is critical to control the pandemic. A prime-boost HIV-1 vaccine trial assessing safety and immunogenicity was conducted in Thailand as part of an evaluation of candidate regimens for a phase 3 efficacy trial. METHODS: ALVAC-HIV (vCP1521), expressing circulating recombinant form 01_AE (CRF01_AE) gp120/subtype B LAI and subtype B Gag/Protease boosted with recombinant envelope oligomeric CRF01_AE gp160 (ogp160) or bivalent CRF01_AE/subtype B gp120 CM235/SF2, was evaluated in a phase 1/II trial of 130 HIV-negative Thai adults. RESULTS: One hundred forty volunteers were enrolled, and 130 completed all safety and immunogenicity visits. Reactogenicity was common but generally mild, and there was no significant difference in the adverse event rate between vaccine and placebo recipients (P = 0.26). There were 7 serious adverse events during the follow-up period, none of which were vaccine related. Cumulative HIV-specific, CD8-mediated, cytotoxic T-lymphocyte responses were observed in 11 (25%) of 44 subjects who received ALVAC boosted by bivalent gp120 and in 5 (11%) of 45 subjects who received ALVAC boosted by ogp160, but these differences were not statistically significant compared with those in placebo recipients (P = 0.62 and P = 0.37, respectively). HIV-specific lymphoproliferative responses were detected in 84% of subunit-boosted vaccine recipients and in 10% of placebo recipients. Neutralizing antibody responses to CRF01_AE and subtype B laboratory strains were seen in 95% of ogp160-boosted and 100% of gp120 B/E-boosted vaccinees, respectively. CONCLUSIONS: These 2 different prime-boost regimens seem to be safe and displayed cell-mediated immune responses consistent with those in other trials of canarypox vectors.
Subject(s)
AIDS Vaccines/immunology , HIV Envelope Protein gp120/immunology , HIV Envelope Protein gp160/immunology , AIDS Vaccines/administration & dosage , AIDS Vaccines/adverse effects , Adult , Cell Proliferation , Double-Blind Method , Female , HIV Antibodies/immunology , HIV Antigens/administration & dosage , HIV Antigens/adverse effects , HIV Antigens/immunology , HIV Envelope Protein gp120/administration & dosage , HIV Envelope Protein gp120/adverse effects , HIV Envelope Protein gp160/administration & dosage , HIV Envelope Protein gp160/adverse effects , HIV Infections/immunology , HIV Infections/prevention & control , Humans , Lymphocytes/immunology , Male , Middle Aged , Protein Binding , VaccinationABSTRACT
An intranasal DNA vaccine prime followed by a gp41 peptide booster immunization was compared with gp41 peptide and control immunizations. Serum HIV-1-specific IgG and IgA as well as IgA in feces and vaginal and lung secretions were detected after immunizations. Long-term humoral immunity was studied for up to 12 mo after the booster immunization by testing the presence of HIV-1 gp41- and CCR5-specific Abs and IgG/IgA-secreting B lymphocytes in spleen and regional lymph nodes in immunized mice. A long-term IgA-specific response in the intestines, vagina, and lungs was obtained in addition to a systemic immune response. Mice immunized only with gp41 peptides and L3 adjuvant developed a long-term gp41-specific serum IgG response systemically, although over a shorter period (1-9 mo), and long-term mucosal gp41-specific IgA immunity. HIV-1-neutralizing serum Abs were induced that were still present 12 mo after booster immunization. HIV-1 SF2-neutralizing fecal and lung IgA was detectable only in the DNA-primed mouse groups. Intranasal DNA prime followed by one peptide/L3 adjuvant booster immunization, but not a peptide prime followed by a DNA booster, was able to induce B cell memory and HIV-1-neutralizing Abs for at least half of a mouse's life span.
Subject(s)
AIDS Vaccines/administration & dosage , HIV Antibodies/biosynthesis , HIV Envelope Protein gp160/administration & dosage , HIV Envelope Protein gp41/administration & dosage , HIV-1/immunology , Nasal Mucosa/immunology , Vaccines, DNA/administration & dosage , Vaccines, Subunit/administration & dosage , AIDS Vaccines/immunology , Administration, Intranasal , Amino Acid Sequence , Animals , B-Lymphocytes/immunology , B-Lymphocytes/virology , Bronchoalveolar Lavage Fluid/immunology , Bronchoalveolar Lavage Fluid/virology , Feces/virology , Female , HIV Envelope Protein gp160/immunology , HIV Envelope Protein gp41/immunology , Immunity, Active , Immunity, Mucosal , Immunization, Secondary/methods , Immunoglobulin A/biosynthesis , Immunoglobulin G/biosynthesis , Immunologic Memory , Intestine, Small/immunology , Intestine, Small/virology , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Nasal Mucosa/virology , Neutralization Tests , T-Lymphocytes/immunology , T-Lymphocytes/virology , Vaccines, DNA/immunology , Vaccines, Subunit/immunology , Vagina/immunology , Vagina/metabolism , Vagina/virologyABSTRACT
Protective or therapeutic immunity against HIV infection is currently believed to require both antibody and CTL responses against the envelope protein. In the present study, the adjuvant activity of a unique oil-in-water emulsion, in which liposomes containing lipid A (LA) and encapsulated antigen served as the emulsifying agent, was examined in mice using oligomeric gp140 (ogp140) derived from the HIV-1 envelope as the antigen. Emulsions rendered either highly stable or unstable by altering the ratio of liposomes to oil were used to examine the effect of stability of the emulsion on adjuvant activity. Stable and unstable emulsions had similar potencies for inducing both IgG antibodies to ogp140 and antigen-specific T-lymphocyte proliferation. Stable emulsions, but not unstable emulsions, induced antigen-specific CTL responses, possibly because of the depot effect of the stable emulsions. Furthermore, stable emulsions induced lower IgG2a/IgG1 ratios than the unstable emulsions. We conclude that stable liposomal oil-in-water emulsions provide an effective means of obtaining both antibody and CTL responses against an HIV envelope antigen.
Subject(s)
AIDS Vaccines/immunology , Adjuvants, Immunologic/chemistry , HIV Antigens/immunology , T-Lymphocytes, Cytotoxic/drug effects , AIDS Vaccines/administration & dosage , AIDS Vaccines/chemistry , Adjuvants, Immunologic/pharmacology , Animals , Drug Stability , Emulsions/chemistry , Emulsions/pharmacology , HIV Antigens/administration & dosage , HIV Envelope Protein gp160/administration & dosage , HIV Envelope Protein gp160/immunology , Immunoglobulin G/analysis , Liposomes , Mice , Mice, Inbred BALB C , Oils , Spleen/cytology , T-Lymphocytes, Cytotoxic/immunology , WaterABSTRACT
Candidate human immunodeficiency virus (HIV)-1 vaccines that elicit cytotoxic T lymphocytes may modulate HIV infection, requiring a prototype evaluation to assess participants who become infected with HIV. Of 1497 participants in canarypox HIV-1 vaccine prime-boost trials, 28 (1.9%) acquired HIV-1 infection after vaccination. Median plasma HIV-1 RNA levels (vaccinees, 4.78 log10 copies/mL; placebo recipients, 4.27 log10 copies/mL) and CD4 cell counts (vaccinees, 552 cells/mm3; placebo recipients, 657 cells/mm3) before administration of antiretroviral therapy (ART) and time to a composite end point (plasma HIV-1 RNA level >55,000 copies/mL, CD4 cell count <350 cells/mm3, or initiation of ART) did not differ significantly between vaccinees and placebo recipients (P =.4, P =.1, and P =.7, respectively). Persons who acquire HIV-1 infection while enrolled in HIV-1 vaccine trials can be successfully followed after infection, to determine whether vaccines alter the course of HIV-1 infection.
Subject(s)
AIDS Vaccines/administration & dosage , Avipoxvirus/genetics , HIV Envelope Protein gp120/administration & dosage , HIV Envelope Protein gp160/administration & dosage , HIV Infections/physiopathology , HIV-1/pathogenicity , AIDS Vaccines/immunology , Double-Blind Method , Female , Genetic Vectors/administration & dosage , Genetic Vectors/genetics , Genetic Vectors/immunology , HIV Envelope Protein gp120/genetics , HIV Envelope Protein gp120/immunology , HIV Envelope Protein gp160/genetics , HIV Envelope Protein gp160/immunology , HIV Infections/prevention & control , Humans , Immunization , Immunization, Secondary , Male , RNA, Viral/blood , Recombinant Proteins/administration & dosage , Recombinant Proteins/genetics , Recombinant Proteins/immunologyABSTRACT
This study investigates whether genetically modified orally administered Lactococcus lactis (L lactis) could be used as an HIV vaccine. L lactis is immunogenic and extremely safe when delivered orally. We created a recombinant L lactis vector expressing the envelope protein of HIV on its cell surface. Oral immunization with this vector induced high levels of HIV-specific serum IgG and fecal IgA antibodies. Cell-mediated immune responses also were generated in both the regional lymph nodes and the spleen. Dendritic cells are readily infected by L lactis and appear to play a potential role in mediating the development of these immune responses. The protective efficacy of this vaccine strategy was demonstrated by challenging mice intraperitoneally with an HIV Env-expressing vaccinia virus. Their viral loads were 350-fold lower than those of control mice. These findings support the further development of L lactis-based HIV vaccines.
Subject(s)
AIDS Vaccines , HIV Envelope Protein gp160/administration & dosage , Immunotherapy/methods , Administration, Oral , Animals , Dendritic Cells/immunology , Dendritic Cells/microbiology , Female , Genetic Vectors/therapeutic use , HIV Envelope Protein gp160/genetics , HIV Envelope Protein gp160/immunology , Immunity, Cellular , Immunoglobulin G/analysis , Lactococcus lactis/genetics , Mice , Mice, Inbred BALB C , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Treatment Outcome , Vaccinia virus/drug effects , Viral LoadABSTRACT
Nasal immunization of normal mice with HIVgp160-encapsulated hemagglutinating virus of Japan (HVJ)-liposome induced high titers of gp160-specific neutralizing IgG in serum and IgA in nasal wash, saliva, fecal extract, and vaginal wash, along with both Th1- and Th2-type responses. HIVgp160-specific IgG- and IgA-producing cells were also detected in mononuclear cells isolated from spleen, nasal cavity, salivary gland, intestinal lamina propria, and vaginal tissue of nasally immunized mice. In addition, CD8(+) CTLs were induced in mice nasally immunized with gp160-HVJ-liposome. These findings suggest that two layers of effective HIV-specific humoral and cellular immunity, in mucosal and systemic sites, were induced by this nasal vaccine. In immunodeficient mice, nasal immunization with gp160-HVJ-liposome induced Ag-specific immune responses for the systemic and mucosal compartments of both Th1 (IFN-gamma(-/-)) and Th2 (IL-4(-/-)). In vitro Ag-specific serum IgG Ab and vaginal wash samples possessing IgA and IgG Abs that had been induced by nasal immunization with gp160-HVJ-liposome were able to neutralize a clinically isolated strain of HIV-MN strain isolated from Japanese hemophiliac patients. Taken together, these results suggest that, for the prevention and control of AIDS, nasally administered gp160-HVJ-liposome is a powerful immunization tool that induces necessary Ag-specific immune responses at different stages of HIV infection.
Subject(s)
AIDS Vaccines/immunology , Epitopes, T-Lymphocyte/immunology , HIV Antibodies/biosynthesis , HIV Envelope Protein gp160/immunology , Lymphocyte Activation , Nasal Mucosa/immunology , Sendai virus/immunology , T-Lymphocytes, Cytotoxic/immunology , AIDS Vaccines/administration & dosage , Administration, Intranasal , Amino Acid Sequence , Animals , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/immunology , Antibody-Producing Cells/immunology , Cytotoxicity, Immunologic , Female , HIV Antibodies/blood , HIV Envelope Protein gp160/administration & dosage , HIV-1/immunology , Immunoglobulin A/biosynthesis , Immunoglobulin A/blood , Immunoglobulin G/biosynthesis , Immunoglobulin G/blood , Immunologic Deficiency Syndromes/genetics , Immunologic Deficiency Syndromes/immunology , Liposomes/administration & dosage , Liposomes/immunology , Mice , Mice, Inbred BALB C , Mice, Knockout , Molecular Sequence Data , Nasal Mucosa/metabolism , Neutralization Tests , Th1 Cells/immunology , Th1 Cells/metabolism , Th2 Cells/immunology , Th2 Cells/metabolism , Vagina/immunology , Vagina/metabolismABSTRACT
During primary viral infection, in vivo exposure to high doses of virus causes a loss of Ag-specific CD8(+) T cells. This phenomenon, termed clonal exhaustion, and other mechanisms by which CTLs are deleted are poorly understood. Here we show evidence for a novel form of cell death in which recently stimulated CD8(+) HIV-1 envelope gp160-specific murine CTLs become apoptotic in vitro after brief exposure to free antigenic peptide (P18-I10). Peak apoptosis occurred within 3 h of treatment with peptide, and the level of apoptosis was dependent on both the time after initial stimulation with target cells and the number of targets. Using T cell-specific H-2D(d)/P18-I10 tetramers, we observed that the apoptosis was induced by such complexes. Induction of apoptosis was blocked by cyclosporin A, a caspase 3 inhibitor, and a mitogen-activated protein kinase inhibitor, but not by Abs to either Fas ligand or to TNF-alpha. Thus, these observations suggest the existence of a Fas- or TNF-alpha-independent pathway initiated by TCR signaling that is involved in the rapid induction of CTL apoptosis. Such a pathway may prove important in the mechanism by which virus-specific CTLs are deleted in the presence of high viral burdens.
Subject(s)
Apoptosis/immunology , HIV Antigens/administration & dosage , HIV Envelope Protein gp160/administration & dosage , HIV Envelope Protein gp160/immunology , T-Lymphocytes, Cytotoxic/cytology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Animals , Calcineurin/metabolism , Caspase 3 , Caspases/metabolism , Female , HIV Antigens/genetics , HIV Envelope Protein gp160/genetics , HIV-1/genetics , HIV-1/immunology , In Vitro Techniques , Mice , Mice, Inbred BALB C , Mitogen-Activated Protein Kinases/metabolism , Peptide Fragments/administration & dosage , Peptide Fragments/genetics , Peptide Fragments/immunology , Receptors, Antigen, T-Cell/metabolism , Signal Transduction , T-Lymphocytes, Cytotoxic/metabolismABSTRACT
In order to boost immune responses in persons in whom highly active antiretroviral therapy (HAART) was initiated within 120 days of the onset of symptoms of newly acquired human immunodeficiency virus type 1 (HIV-1) infection, we administered vaccines containing a canarypox virus vector, vCP1452, with HIV-1 genes encoding multiple HIV-1 proteins, and recombinant gp160. Fifteen HIV-1-infected subjects who achieved sustained suppression of plasma viremia for at least 2 years were enrolled. While continuing antiretroviral therapy, each subject received at least four intramuscular injections of the vaccines on days 0, 30, 90, and 180. Adverse events were mild, with the most common being transient tenderness at the vCP1452 injection site. Of the 14 patients who completed vaccination, 13 had significant increases in anti-gp120 or anti-p24 antibody titers, and 9 had transient augmentation of their T-cell proliferation responses to gp160 and/or p24. HIV-1-specific CD8(+) T cells were quantified using an intracellular gamma interferon staining assay. Among 11 patients who had increased CD8(+) T-cell responses, seven had responses to more than one HIV-1 antigen. In summary, vaccination with vCP1452 and recombinant gp160 appears safe and immunogenic in newly HIV-1-infected patients on HAART.
Subject(s)
AIDS Vaccines/immunology , Antiretroviral Therapy, Highly Active , HIV Envelope Protein gp160/immunology , HIV Infections/immunology , HIV-1 , Viral Vaccines/immunology , AIDS Vaccines/administration & dosage , AIDS Vaccines/adverse effects , AIDS Vaccines/genetics , Female , HIV Antibodies/blood , HIV Envelope Protein gp160/administration & dosage , HIV Envelope Protein gp160/adverse effects , HIV Envelope Protein gp160/genetics , HIV Infections/drug therapy , HIV Infections/virology , HIV-1/genetics , HIV-1/immunology , Humans , Male , RNA, Viral/blood , Recombination, Genetic , T-Lymphocytes/immunology , Vaccination , Vaccines, Combined , Viral Vaccines/administration & dosage , Viral Vaccines/adverse effects , Viral Vaccines/geneticsABSTRACT
The topical application of DNA vaccine to the skin is a useful method of immunization because of its simplicity, painlessness and economy. But the immune responses that it elicits are relatively low. In this study, we administered human immunodeficiency virus type-1 (HIV-1) DNA vaccine with cytokine-expressing plasmids to the skin of mice by a new topical application technique involving prior elimination of keratinocytes using fast-acting adhesive. Our results revealed that the topical application of HIV-1 DNA vaccine induced high levels of both humoral and cell-mediated immune activity against HIV-1 envelope antigen. Co-administration of the DNA vaccine with cytokine expression plasmids of IL-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF) by this new method raised the levels of both the HIV-specific cytotoxic T lymphocyte (CTL) response and delayed-type hypersensitivity (DTH) and facilitated the induction of substantial immune responses by DNA vaccine. Skin biopsy sections, thus, immunized showed significant increases of S-100 protein-positive dendritic cells (DCs). These results suggest that the topical application method described here is an efficient route of DNA vaccine administration and that the immune response may be induced by DNA plasmids taken in by DCs, Langerhans cells (LCs), or others such as antigen-presenting cells. This new topical application is likely to be of benefit in clinical use.
Subject(s)
AIDS Vaccines/administration & dosage , Gene Products, rev/administration & dosage , Granulocyte-Macrophage Colony-Stimulating Factor/genetics , HIV Antibodies/biosynthesis , HIV Antigens/immunology , HIV Envelope Protein gp120/administration & dosage , HIV Envelope Protein gp160/administration & dosage , HIV-1/immunology , Interleukin-12/genetics , Peptide Fragments/administration & dosage , AIDS Vaccines/immunology , Administration, Cutaneous , Animals , Biomarkers , Biopsy , Dermabrasion , Drug Evaluation, Preclinical , Enzyme-Linked Immunosorbent Assay , Female , Gene Products, rev/genetics , Gene Products, rev/immunology , HIV Antigens/genetics , HIV Envelope Protein gp120/genetics , HIV Envelope Protein gp120/immunology , HIV Envelope Protein gp160/genetics , HIV Envelope Protein gp160/immunology , HIV-1/genetics , Hypersensitivity, Delayed/immunology , Immunity, Cellular , Langerhans Cells/immunology , Mice , Mice, Inbred BALB C , Peptide Fragments/genetics , Peptide Fragments/immunology , Plasmids/administration & dosage , Plasmids/genetics , Recombinant Fusion Proteins/genetics , S100 Proteins/analysis , Skin/immunology , Skin/pathology , T-Lymphocytes, Cytotoxic/immunology , Vaccines, DNA/administration & dosage , Vaccines, DNA/immunology , rev Gene Products, Human Immunodeficiency VirusABSTRACT
The aim of the study was to investigate the safety of an HIV-1 gp160 plasmid vaccine. Four asymptomatic HIV-1-infected subjects with CD4+ lymphocyte counts >500/microl were injected with four times 400 microg of HIV-1 modified gp160 env and rev coding DNA vaccine at 0, 4, 10 and 28 weeks. Safety parameters, including autoimmune antibodies as well as CD4+/CD8+ cell counts and HIV-1 plasma concentrations, were monitored for 52 weeks after the first vaccine application. Follow-up data for more than 3 years are now available. The DNA vaccine proved to be safe and, specifically, did not induce anti-DNA autoimmune antibodies. Vaccination had no long-term effects on the CD4+/CD8+ lymphocyte counts, plasma HIV-1 RNA concentrations or disease progression. The present data supplement published data from Philadelphia, USA, where a dose-escalating study (30-300 microg) with the same HIV-1 DNA vaccine was performed.
Subject(s)
AIDS Vaccines/administration & dosage , HIV Envelope Protein gp160/administration & dosage , HIV Infections/prevention & control , HIV-1/immunology , Vaccination/methods , Adult , Female , Follow-Up Studies , HIV Envelope Protein gp160/immunology , HIV Seropositivity , Humans , Immunization Schedule , Male , Patient Selection , Severity of Illness Index , Treatment OutcomeABSTRACT
Immunization with a recombinant glycoprotein 160 envelope immunogen derived from a virus of genetic subtype B induced strong specific T-helper cell responses in asymptomatic human immunodeficiency virus (HIV) carriers infected with subtypes B to G. This indicates that the HIV-specific T-helper immunity, which is the basis for development of antibodies and cytotoxic T lymphocytes, can be improved by both homologous and heterologous antigens. It also suggests that a particular immunogen can be effective against many different HIV strains.
Subject(s)
AIDS Vaccines/immunology , HIV Infections/immunology , HIV-1/immunology , T-Lymphocytes, Helper-Inducer/immunology , AIDS Vaccines/administration & dosage , Cross Reactions , HIV Envelope Protein gp160/administration & dosage , HIV Envelope Protein gp160/genetics , HIV Envelope Protein gp160/immunology , HIV Infections/virology , HIV-1/classification , Humans , Lymphocyte Activation , Vaccination , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunologyABSTRACT
This longitudinal study was designed to evaluate cellular immunity in early-stage, asymptomatic human immunodeficiency virus (HIV)-1-infected persons (CD4 cell count,>400/mm3; median, 625/mm3) who were immunized with either recombinant (r) gp160 or placebo every 2 months for 5 years. Proliferative responses were assessed against rgp160, rp24, and a panel of recall antigens and mitogens. Despite good reactivity to recall antigens, at baseline approximately 33% had proliferative responses to gp160, and approximately 42% showed p24 gag responses. There was no statistical difference between vaccine and placebo groups for antigens or mitogens. After 1 year, approximately 73% of the subjects in the vaccine arm had new or boosted responses to gp160, versus approximately 18% in the placebo arm. Statistical significance was maintained throughout the study. Recurrent vaccination with recombinant gp160 was proven to be persistently immunogenic, increasing significantly the ability of HIV-1-infected persons to mount new proliferative responses to the vaccine.